{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:07:32Z","timestamp":1789628852694,"version":"build-2803163510"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jhepr.2026.102023","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:53:04Z","timestamp":1789627984000},"page":"102023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Promises and Pitfalls of ctDNA testing in the Management of Cholangiocarcinoma"],"prefix":"10.1016","author":[{"given":"Mingen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Doger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9696-6122","authenticated-orcid":false,"given":"Angela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipika","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.102023_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2407-2-10","article-title":"Worldwide trends in mortality from biliary tract malignancies","volume":"2","author":"Patel","year":"2002","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2026.102023_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12876-016-0527-z","article-title":"Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database","volume":"16","author":"Yao","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102023_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102023_bib4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2026.102023_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.jhepr.2026.102023_bib6","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics In. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Surveillance Research Program, National Cancer Institute 2023"},{"key":"10.1016\/j.jhepr.2026.102023_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.sla.0000150166.94732.88","article-title":"Actual long-term outcome of extrahepatic bile duct cancer after surgical resection","volume":"241","author":"Jang","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhepr.2026.102023_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092854","article-title":"Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhepr.2026.102023_bib9","article-title":"Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma","volume":"11","author":"Wintachai","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jhepr.2026.102023_bib10","unstructured":"Lapitz A, Azkargorta M, Milkiewicz P et al. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma."},{"key":"10.1016\/j.jhepr.2026.102023_bib11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jhepr.2026.102023_bib13","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib14","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102023_bib16","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.102023_bib17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12885-021-07788-7","article-title":"Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2026.102023_bib18","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41416-022-01932-1","article-title":"Precision oncology for intrahepatic cholangiocarcinoma in clinical practice","volume":"127","author":"Tomczak","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2026.102023_bib19","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.102023_bib20","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102023_bib21","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: Utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2026.102023_bib22","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.102023_bib23","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib24","doi-asserted-by":"crossref","unstructured":"Mody K, Kasi PM, Yang J et al. Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. JCO Precision Oncology 2019; 1-9.","DOI":"10.1200\/PO.18.00324"},{"key":"10.1016\/j.jhepr.2026.102023_bib25","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jnci\/djad046","article-title":"Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma","volume":"115","author":"Spencer","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhepr.2026.102023_bib26","article-title":"Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer","author":"Hwang","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102023_bib27","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-23-3780","article-title":"Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy","volume":"30","author":"Gonz\u00e1lez-Medina","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.102023_bib28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.22.02636","article-title":"MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2\u2013Altered Advanced Solid Tumors","volume":"42","author":"Sweeney","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jhepr.2026.102023_bib29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2024.10.043","article-title":"Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma","volume":"82","author":"Yoo","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102023_bib30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102023_bib31","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102023_bib32","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.102023_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.4576","article-title":"IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study","volume":"38","author":"Aguado","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jhepr.2026.102023_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib35","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.102023_bib36","article-title":"Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy","volume":"6","author":"Uson Junior","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.102023_bib38","article-title":"Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations","volume":"5","author":"Varghese","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib39","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.102023_bib40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.102023_bib41","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","article-title":"A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.434","article-title":"Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial","volume":"42","author":"Javle","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jhepr.2026.102023_bib43","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.102023_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib45","unstructured":"Wan JA-O, Saatcioglu HA-O, Ellis HA-O et al. MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response."},{"key":"10.1016\/j.jhepr.2026.102023_bib46","article-title":"Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors","volume":"6","author":"Lapin","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib47","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1593\/neo.121106","article-title":"The N550K\/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors","volume":"15","author":"Byron","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.jhepr.2026.102023_bib48","unstructured":"DiPeri TP, Zhao M, Evans KW et al. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma."},{"key":"10.1016\/j.jhepr.2026.102023_bib49","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2026.102023_bib50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","article-title":"Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer","volume":"608","author":"Herberts","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.102023_bib51","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/annonc\/mdu239","article-title":"Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle","volume":"25","author":"De Mattos-Arruda","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib52","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","article-title":"Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid","volume":"565","author":"Miller","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.102023_bib53","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a004002","article-title":"Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy","volume":"5","author":"Krook","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.jhepr.2026.102023_bib54","unstructured":"Tie J, Cohen JD, Wang Y et al. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer."},{"key":"10.1016\/j.jhepr.2026.102023_bib55","unstructured":"Tie J, Wang Y, Tomasetti C et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer."},{"key":"10.1016\/j.jhepr.2026.102023_bib56","unstructured":"Tie JA-O, Cohen JD, Lahouel KA-O et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer."},{"key":"10.1016\/j.jhepr.2026.102023_bib57","unstructured":"Sahin Ih Fau - Lin Y, Lin Y Fau - Yothers G, Yothers G Fau - Lucas PC et al. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US."},{"issue":"5","key":"10.1016\/j.jhepr.2026.102023_bib58","article-title":"Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II\/III study","volume":"42","author":"al","year":"2024","journal-title":"ASCO 2024 - J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib59","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","article-title":"Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","volume":"39","author":"Deveson","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhepr.2026.102023_bib60","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1038\/s41598-020-60375-x","article-title":"Comparison of Target Enrichment Platforms for Circulating Tumor DNA Detection","volume":"10","author":"Lam","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.102023_bib61","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.102023_bib62","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12967-020-02449-y","article-title":"Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors","volume":"18","author":"Li","year":"2020","journal-title":"J Transl Med"},{"key":"10.1016\/j.jhepr.2026.102023_bib63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"29","author":"Kotani","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.102023_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047831","article-title":"BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer","volume":"11","author":"Kasi","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhepr.2026.102023_bib65","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jhepr.2026.102023_bib66","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41418-024-01272-y","article-title":"Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck","volume":"31","author":"Sanz-Garcia","year":"2024","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jhepr.2026.102023_bib67","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216505","article-title":"Comparison of tumor-informed and tumor-na\u00efve sequencing assays for ctDNA detection in breast cancer","volume":"15","author":"Santonja","year":"2023","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jhepr.2026.102023_bib68","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.CCR-21-2136","article-title":"The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jhepr.2026.102023_bib69","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/humu.22825","article-title":"Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing","volume":"36","author":"Samorodnitsky","year":"2015","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jhepr.2026.102023_bib70","article-title":"Circulating tumor DNA enables sensitive detection of actionable gene fusions and rearrangements across cancer types","author":"Kasi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.102023_bib71","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2019.06.004","article-title":"Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA","volume":"134","author":"Supplee","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jhepr.2026.102023_bib72","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cytogfr.2019.12.005","article-title":"Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma","volume":"52","author":"Li","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jhepr.2026.102023_bib73","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2026.102023_bib74","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41416-021-01536-1","article-title":"NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types","volume":"126","author":"Rolfo","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2026.102023_bib75","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance","volume":"14","author":"Schram","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib76","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-19-0372","article-title":"Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms","volume":"79","author":"Solomon","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2026.102023_bib77","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.tranon.2019.02.012","article-title":"An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer","volume":"12","author":"Haynes","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib78","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.102023_bib79","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ajhg.2021.03.014","article-title":"Expectations and blind spots for structural variation detection from long-read assemblies and short-read genome sequencing technologies","volume":"108","author":"Zhao","year":"2021","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jhepr.2026.102023_bib80","article-title":"Long-read sequencing of diagnosis and post-therapy medulloblastoma reveals complex rearrangement patterns and epigenetic signatures","volume":"3","author":"Rausch","year":"2023","journal-title":"Cell Genom"},{"key":"10.1016\/j.jhepr.2026.102023_bib81","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41525-021-00272-y","article-title":"Accurate detection of circulating tumor DNA using nanopore consensus sequencing","volume":"6","author":"Marcozzi","year":"2021","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.jhepr.2026.102023_bib82","unstructured":"Gawro\u0144ski AR, Lin YY, McConeghy B et al. Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA."},{"key":"10.1016\/j.jhepr.2026.102023_bib83","unstructured":"Rodon J, Prenen H, Sacher A et al. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration."},{"key":"10.1016\/j.jhepr.2026.102023_bib84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41467-020-20162-8","article-title":"Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.102023_bib85","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1158\/1078-0432.CCR-20-3677","article-title":"Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study","volume":"27","author":"Kagawa","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.102023_bib86","article-title":"Tumor-Informed Versus Plasma-Only Liquid Biopsy Assay in a Patient With Multiple Primary Malignancies","volume":"6","author":"Kasi","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib87","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1038\/s41598-020-60559-5","article-title":"Systematic comparison of somatic variant calling performance among different sequencing depth and mutation frequency","volume":"10","author":"Chen","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.102023_bib88","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102023_bib89","first-page":"4990","article-title":"Genomic mutation characteristics and prognosis of biliary tract cancer","volume":"14","author":"Guo","year":"2022","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jhepr.2026.102023_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103103","article-title":"Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA","volume":"62","author":"Dietz","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhepr.2026.102023_bib91","article-title":"Non-invasive detection of biliary tract cancer by low-coverage whole genome sequencing from plasma cell-free DNA: A prospective cohort study","volume":"14","author":"Wang","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib92","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-022-30708-7","article-title":"The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.102023_bib93","article-title":"Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients","volume":"4","author":"Cao","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib94","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/onco.13844","article-title":"Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns","volume":"26","author":"Israel","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2026.102023_bib95","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nbt.1596","article-title":"Building the sequence map of the human pan-genome","volume":"28","author":"Li","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhepr.2026.102023_bib96","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41586-023-05896-x","article-title":"A draft human pangenome reference","volume":"617","author":"Liao","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.102023_bib97","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1038\/s41467-022-33073-7","article-title":"Pangenomic analysis of Chinese gastric cancer","volume":"13","author":"Yu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.102023_bib98","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1101\/gr.213611.116","article-title":"Evaluation of GRCh38 and de novo haploid genome assemblies demonstrates the enduring quality of the reference assembly","volume":"27","author":"Schneider","year":"2017","journal-title":"Genome Res"},{"key":"10.1016\/j.jhepr.2026.102023_bib99","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1038\/sj.onc.1205651","article-title":"DNA methylation in cancer: too much, but also too little","volume":"21","author":"Ehrlich","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.jhepr.2026.102023_bib100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(03)01115-X","article-title":"Relevance of DNA methylation in the management of cancer","volume":"4","author":"Esteller","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib101","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1530\/ERC-15-0369","article-title":"Methylated circulating tumor DNA in blood: power in cancer prognosis and response","volume":"23","author":"Warton","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jhepr.2026.102023_bib102","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12916-021-02197-w","article-title":"Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes","volume":"20","author":"Qiu","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.jhepr.2026.102023_bib103","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib104","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","article-title":"Sensitive tumour detection and classification using plasma cell-free DNA methylomes","volume":"563","author":"Shen","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.102023_bib105","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa2304714","article-title":"A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening","volume":"390","author":"Chung","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jhepr.2026.102023_bib106","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.annonc.2019.11.014","article-title":"Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer","volume":"31","author":"Moss","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib107","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/2159-8290.CD-21-0090","article-title":"Artificial Intelligence in Cancer Research and Precision Medicine","volume":"11","author":"Bhinder","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.102023_bib108","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tig.2023.01.004","article-title":"Bridging biological cfDNA features and machine learning approaches","volume":"39","author":"Moser","year":"2023","journal-title":"Trends Genet"},{"key":"10.1016\/j.jhepr.2026.102023_bib109","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41551-021-00746-5","article-title":"Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning","volume":"5","author":"Liang","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jhepr.2026.102023_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.790645","article-title":"Precision Oncology: Artificial Intelligence and DNA Methylation Analysis of Circulating Cell-Free DNA for Lung Cancer Detection","volume":"12","author":"Bahado-Singh","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2026.102023_bib111","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1186\/s12885-019-6003-8","article-title":"Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA","volume":"19","author":"Wan","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2026.102023_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102811","article-title":"Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma","volume":"56","author":"Tao","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhepr.2026.102023_bib113","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.1038\/s41467-022-35076-w","article-title":"A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA","volume":"13","author":"Doebley","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.102023_bib114","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1038\/s41467-021-23445-w","article-title":"Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden","volume":"12","author":"Peneder","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.102023_bib115","article-title":"Optimization of bile preparation for liquid biopsy in cholangiocarcinoma focusing on circulating tumor DNA and protein stability","volume":"15","author":"Han","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.102023_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115633","article-title":"Shallow whole-genome sequencing of circulating tumour DNA predicts clinical outcomes to systemic therapy in advanced hepatocellular carcinoma","volume":"227","author":"Mallela","year":"2025","journal-title":"Eur J Cancer"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:53:29Z","timestamp":1789628009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926002946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":116,"alternative-id":["S2589555926002946"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102023","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Promises and Pitfalls of ctDNA testing in the Management of Cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"102023"}}